MI Sign Up for eTOC Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smyth, M. J.
Right arrow Articles by Kershaw, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smyth, M. J.
Right arrow Articles by Kershaw, M. H.
Molecular Interventions 3:186-189 (2003)
© 2003 American Society of Pharmacology and Experimental Therapeutics

Viewpoint

Discovery of an Innate Cancer Resistance Gene?

Mark J. Smyth and Michael H. Kershaw

Cancer Immunology Program Peter MacCallum Cancer Centre East Melbourne, 3002, Victoria, Australia

SUMMARY

Advances in cancer research have exploited the knowledge that mutations in proto-oncogenes and/or mutations in both alleles of tumor suppressor genes can bring about the cancer phenotype. Research originating from the opposite side of the coin—cancer-resistance genetics—has been less spectacular. Nonetheless, Cui et al. have observed one BALB/c mouse that did not bear tumors after receiving repeated injections of highly aggressive tumor cells. After breeding a colony of cancer-resistant mice from the resistant founder, the authors found that the trait was inherited in simple Mendelian dominant fashion, most likely under the control of a single locus. Intriguingly, this resistance trait disappears with age.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.